SLC6A4 and Alzheimer disease: As a novel compound with the highest PhaseScreenScore, there appeared S1 [49], developed in a study exploring a novel dual receptor for advanced glycation end products (RAGE)/SERT inhibitors for potential application in treating co-morbid AD and depression.